J Bacteriol Virol.  2009 Sep;39(3):217-227. 10.4167/jbv.2009.39.3.217.

In vitro Expansion of Natural Regulatory T Lymphocytes Useful for Cell Therapy in Allotransplantation

• Park YH
• Koo SK
• Lee YJ
• Joe IY
• Kim SC
• Han DJ
• Lim DG

• KMID: 1474164
• DOI: http://doi.org/10.4167/jbv.2009.39.3.217

Abstract

Immunotherapy with regulatory T lymphocytes is considered to be an attractive new therapeutic modality to prevent allograft rejection. The success of this new therapy is critically dependent on the preparation of highly effective and enough number of regulatory T cells. Here, we tried to establish a proper strategy for the ex vivo expansion of regulatory T cells and evaluated their characteristics. CD4+CD25h+CD62L+ T cells were isolated from the recipient mice and weekly stimulated with various stimuli in the presence of IL-2. The most efficient protocol for the expansion of regulatory T cells maintaining Foxp3 expression and regulatory activity was the three cycles stimulation with donor bone marrow-derived dendritic cells (BM-DCs) which yielded around 400 fold expansion of regulatory T cells. The in vitro-expanded regulatory T cells expressing lymph node homing receptors on their cell surface, were composed of polyclonal population, and did not acquire the ability to produce effector cytokines. Importantly, these expanded regulatory T cells induced a modest prolongation of skin allograft survival when combined with transient T cell depletion in recipient mice. These data indicate that our protocol could be used to obtain an effective population of natural regulatory T cells available for the regulatory T cell therapy to prevent allograft rejection.

Keyword

Regulatory T lymphocyte; Cell therapy; Allograft rejection; Ex vivo expansion

MeSH Terms

Animals
Cytokines
Dendritic Cells
Humans
Immunotherapy
Interleukin-2
Mice
Receptors, Lymphocyte Homing
Rejection (Psychology)
Skin
T-Lymphocytes
T-Lymphocytes, Regulatory
Tissue Donors
Tissue Therapy
Transplantation, Homologous
Cytokines
Interleukin-2
Receptors, Lymphocyte Homing

Figure

• 

  Figure 1. Isolation of nTreg cells. CD4+ T cells were isolated from spleen/LN cells of normal C57BL/6 mice using MACS CD4+ T cell isolation kit, and then they were stained with FITC-CD4, PE-CD25, and PE-Cy5-CD62L. CD4+CD25h+CD62L+ T cells were purified by FACSorting. The expression of Foxp3 was determined by intracellular staining with APC-anti-Foxp3 Ab.

• 

  Figure 2. Ex vivo expansion of nTreg cells. Purified nTreg cells were weekly stimulated with allo-APCs or anti-CD3 & CD28-coated beads in the presence of 500 U/ml rIL-2. At the end of each stimulation cycles, viable cells were harvested and counted to calculate the expansion fold. The percentage of Foxp3-expressing cells was determined by intracellular staining with specific Ab. The suppressive activity of cultured nTreg cells was examined by their ability to inhibit the proliferation of responder T cells in MLR.

• 

  Figure 3. Expression level of Foxp3 mRNA after repeated in vitro stimulation. The amount of Foxp3 mRNA in nTreg cells at the end of each stimulation cycles (black bar; None) or one day after restimulation (gray bar; Act) with allogeneic BM-DCs was determined by real-time RT-PCR. Foxp3 levels are shown relative to that observed in nTregs at the end of first stimulation cycle. N.D. represents ‘not determined’; the recovered cell number of Tregs was not enough to perform the experiment after first stimulation culture.

• 

  Figure 4. Expression of lymph node homing receptors in in vitro-expanded nTreg cells. In vitro-expanded nTreg cells by three cycles of stimulation with allogeneic BM-DCs were stained with specific and control antibodies. Percentage of CD62L and CCR7 positive cells is shown in each corresponding quadrant.

• 

  Figure 5. The absence of effector cytokine secretion from in vitro-expanded nTreg cells. The cytokine secretion was examined by intracellular cytokine staining with each cytokine-specific antibodies after restimulation of cells with PMA and ionomycin. Tresp line was prepared from CD4+CD25– T cells after repeated stimulation with allogeneic BM-DCs using the same protocol as used in Treg cell expansion. Gray filled and black line histogram represent isotype control antibody and cytokine specific antibody-stained cells, respectively.

• 

  Figure 6. TCR Vβ chain usage of nTreg cells. Naïve or in vitro-expanded nTreg cells by three rounds of stimulation were stained with FITC-conjugated mAbs which recognize mouse Vβ chains. The percent of cells having specific TCR Vβ chain among total CD4+ T cells was displayed. The stimuli used in each cycles of stimulation were shown in the right parenthesis of each graph.

• 

  Figure 7. The therapeutic effect of in vitro-expanded nTreg cells on skin allograft survival. In vitro-expanded nTreg cells (1 × 107/mouse) were intravenously injected prior to engraftment of skin on the same day and one more time 2~3 days after skin grafting. In some recipient mice, endogenous T cells were transiently depleted by the administration of depleting anti-CD4 and anti-CD8 mAbs 14 days prior to receiving skin allograft. MHC fully mismatched skin grafting (BALB/c → C57BL/6) was conducted in recipient mice without any manipulation (None), or with either adoptive transfer of nTreg or transient lymphodepletion alone, or together.

Reference

1). Dantal J., Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med. 2005. 352:1371–3.

2). Lechler RI., Garden OA., Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol. 2003. 3:147–58.

3). Zhang ZX., Yang L., Young KJ., DuTemple B., Zhang L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med. 2000. 6:782–9.

4). Taylor PA., Noelle RJ., Blazar BR. CD4⁺CD25⁺ immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med. 2001. 193:1311–8.

5). Hoffmann P., Ermann J., Edinger M., Fathman CG., Strober S. Donor-type CD4⁺CD25⁺ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002. 196:389–99.

6). Davies JD., O'Connor E., Hall D., Krahl T., Trotter J., Sarvetnick N. CD4⁺ CD45RB low-density cells from untreated mice prevent acute allograft rejection. J Immunol. 1999. 163:5353–7.

7). Hara M., Kingsley CI., Niimi M., Read S., Turvey SE., Bushell AR., Morris PJ., Powrie F., Wood KJ. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol. 2001. 166:3789–96.

8). Ciubotariu R., Colovai AI., Pennesi G., Liu Z., Smith D., Berlocco P., Cortesini R., Suciu-Foca N. Specific suppression of human CD4⁺ T_H-cell responses to pig MHC antigens by CD8⁺CD28^– regulatory T cells. J Immunol. 1998. 161:5193–202.

9). Bluestone JA., Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003. 3:253–7.

10). Shevach EM. CD4⁺CD25⁺ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002. 2:389–400.

11). Jonuleit H., Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol. 2003. 171:6323–7.

12). Daley SR., Ma J., Adams E., Cobbold SP., Waldmann H. A key role for TGF-β signaling to T cells in the long-term acceptance of allografts. J Immunol. 2007. 179:3648–54.

13). Carvalho-Gaspar M., Jones ND., Luo S., Martin L., Brook MO., Wood KJ. Location and time-dependent control of rejection by regulatory T cells culminates in a failure to generate memory T cells. J Immunol. 2008. 180:6640–8.

14). Wan YY., Flavell RA. The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol Rev. 2006. 212:114–30.

15). Takahashi T., Kuniyasu Y., Toda M., Sakaguchi N., Itoh M., Iwata M., Shimizu J., Sakaguchi S. Immunologic self-tolerance maintained by CD25⁺CD4⁺ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998. 10:1969–80.

16). Taylor PA., Lees CJ., Blazar BR. The infusion of ex vivo activated and expanded CD4⁺CD25⁺ immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002. 99:3493–9.

17). Yamazaki S., Iyoda T., Tarbell K., Olson K., Velinzon K., Inaba K., Steinman RM. Direct expansion of functional CD25⁺CD4⁺ regulatory T cells by antigen-processing dendritic cells. J Exp Med. 2003. 198:235–47.

18). Tang Q., Henriksen KJ., Bi M., Finger EB., Szot G., Ye J., Masteller EL., McDevitt H., Bonyhadi M., Bluestone JA. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004. 199:1455–65.

19). Tarbell KV., Yamazaki S., Olson K., Toy P., Steinman RM. CD25⁺CD4⁺ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med. 2004. 199:1467–77.

20). Chai JG., Coe D., Chen D., Simpson E., Dyson J., Scott D. In vitro expansion improves in vivo regulation by CD4⁺CD25⁺ regulatory T cells. J Immunol. 2008. 180:858–69.

21). Sanchez-Fueyo A., Sandner S., Habicht A., Mariat C., Kenny J., Degauque N., Zheng XX., Strom TB., Turka LA., Sayegh MH. Specificity of CD4⁺CD25⁺ regulatory T cell function in alloimmunity. J Immunol. 2006. 176:329–34.

22). Peters JH., Hilbrands LB., Koenen HJ., Joosten I. Ex vivo generation of human alloantigen-specific regulatory T cells from CD4^posCD25^high T cells for immunotherapy. PLoS One. 2008. 3:e2233.

23). Huehn J., Siegmund K., Lehmann JC., Siewert C., Haubold U., Feuerer M., Debes GF., Lauber J., Frey O., Przybylski GK., Niesner U., de la Rosa M., Schmidt CA., Brauer R., Buer J., Scheffold A., Hamann A. Developmental stage, phenotype, and migration distinguish naïve- and effector/memory-like CD4⁺ regulatory T cells. J Exp Med. 2004. 199:303–13.

24). Suchin EJ., Langmuir PB., Palmer E., Sayegh MH., Wells AD., Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol. 2001. 166:973–81.

25). Shevach EM. Mechanisms of Foxp3⁺ T regulatory cell-mediated suppression. Immunity. 2009. 30:636–45.